-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Scientists in Adelaide, Australia, are developing a potential new vaccine that has passed the first phase of human trials and is expected to be available within the next three to four months.
reported that the vaccine, called COVAX-19, was tested in humans earlier this month on 40 volunteers who developed an immune response.
said the vaccine was the first candidate to pass a phase i-phase clinical trial in Australia.
reported that the second phase of the COVAX-19 trial, which will require 400 to 500 volunteers, will begin in September.
, the team has also been in talks with the Governments of the United Kingdom and Canada over funding for the third phase of the trial, which will provide up to 50,000 volunteers with the vaccine. "This will be the last step before the vaccine can be made available to the general public," said Petrovsky, a professor at Flinders University in
.
if all goes well, the vaccine could be available within the next three to four months.
" name source: China News Network !-- content display end- !-- determine whether the login ends.